Quantcast

Latest Becker's muscular dystrophy Stories

2010-09-24 01:00:00

AMSTERDAM, September 24, 2010 /PRNewswire-FirstCall/ -- Amsterdam Molecular Therapeutics (AMT) Holding N.V. (Euronext: AMT), a leader in the field of human gene therapy, announced today that the U.S. Food and Drug Administration (FDA) has designated AMT-080, a gene therapy for Duchenne muscular dystrophy (DMD) as an orphan drug. In October 2009, the Committee for Orphan Medical Products of the European Medicines Agency granted AMT-080 orphan designation for the same indication in the...

2010-09-03 07:47:00

$11 Million Supports Five-Year Study to Compare Treatments ROCHESTER, N.Y., Sept. 3 /PRNewswire-USNewswire/ -- A large international study aimed at improving the care of muscular dystrophy patients worldwide is being launched by physicians, physical therapists, and researchers at the University of Rochester Medical Center. Neurologist Robert "Berch" Griggs, M.D., is heading the study of treatments for Duchenne muscular dystrophy, the most common form of the disease that affects children....

2010-08-09 12:14:00

Dr. Jerry Mendell Leading Follistatin Gene Therapy MIDDLETOWN, Ohio, Aug. 9 /PRNewswire-USNewswire/ -- Parent Project Muscular Dystrophy (PPMD), the largest non-profit organization in the United States focused on finding a cure for Duchenne muscular dystrophy (Duchenne), will award a $600,000 grant to Nationwide Children's Hospital in Columbus, Ohio to conduct clinical testing of a promising gene therapy technique for muscle disease. (Logo:...

2010-07-14 09:55:00

Funds Will Help Offset Travel Costs for Participants MIDDLETOWN, Ohio, July 14 /PRNewswire-USNewswire/ -- Patricia A. Furlong, Founding President and CEO of Parent Project Muscular Dystrophy (PPMD), the largest non-profit organization in the United States focused on finding a cure for Duchenne muscular dystrophy (Duchenne), announced that PPMD will provide a grant to clinical sites participating in Acceleron Pharma's Phase 2 clinical study of ACE-031. These grants will help patients'...

2010-06-18 09:30:00

Conference Includes Launch of First-Ever Duchenne Therapeutic Development Meeting MIDDLETOWN, Ohio, June 18 /PRNewswire-USNewswire/ -- Patricia A. Furlong, Founding President and CEO of Parent Project Muscular Dystrophy (PPMD), the largest non-profit organization in the United States focused on finding a cure for Duchenne muscular dystrophy (Duchenne), announced that the Mayor of Denver, Colorado, John W. Hickenlooper, has proclaimed June 26, 2010 "End Duchenne Day" in recognition of...

2010-06-10 09:00:00

Dr. Dongsheng Duan and Nicholas Dobes to Receive Grants MIDDLETOWN, Ohio, June 10 /PRNewswire-USNewswire/ -- Patricia A. Furlong, Founding President and CEO of Parent Project Muscular Dystrophy (PPMD), the largest non-profit organization in the United States focused on finding a cure for Duchenne muscular dystrophy (Duchenne), announced today that PPMD will be funding two critical, promising research initiatives in Duchenne. (Logo: http://photos.prnewswire.com/prnh/20100119/DC39975LOGO)...

2010-06-08 19:06:20

Loyola Scientist Describes Gene Research in Journal Article One in 25 people from India and other south Asian countries carries a mutated gene that causes heart failure. Studying this gene, and the protein it encodes, could lead to new treatments for heart failure, Loyola University Health System researcher Sakthivel Sadayappan, PhD, wrote in a recent review article in the Journal of Molecular and Cellular Cardiology. Sadayappan has studied the gene and protein for 15 years. Investigating the...

2010-05-14 12:00:00

Rep. Thomas R. Caltagirone Makes Disease Awareness Priority After Meeting Local Boy HARRISBURG, Pa., May 14 /PRNewswire-USNewswire/ -- The Pennsylvania House of Representatives has passed a resolution declaring the week of May 24, 2010 as "Duchenne Muscular Dystrophy Awareness Week" to help honor the work of Parent Project Muscular Dystrophy (PPMD), the largest non-profit organization in the United States focused on finding a cure for Duchenne muscular dystrophy (Duchenne). The resolution...

2010-05-07 14:31:00

MIDDLETOWN, Ohio, May 7 /PRNewswire-USNewswire/ -- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and the National Institute of Neurological Disorders and Stroke (NINDS) are launching a five-year, $7.5 million natural history study of Duchenne muscular dystrophy (Duchenne), a degenerative genetically-linked neuromuscular disease. The study aims to validate non-invasive approaches to monitor the progression and treatment of Duchenne, and holds potential to...

2010-04-15 13:54:03

Researchers from Universit© Laval's Faculty of Medicine and the CHUQ Research Center have proven that it is possible to repair the defective gene responsible for Duchenne muscular dystrophy. The team, led by Professor Jacques P. Tremblay, is presenting its new therapeutic approach in an article published today in the online version of the scientific journal Gene Therapy. Duchenne muscular dystrophy is a hereditary disease affecting one in 3,500 males. It causes progressive muscle...


Word of the Day
sough
  • A murmuring sound; a rushing or whistling sound, like that of the wind; a deep sigh.
  • A gentle breeze; a waft; a breath.
  • Any rumor that engages general attention.
  • A cant or whining mode of speaking, especially in preaching or praying; the chant or recitative characteristic of the old Presbyterians in Scotland.
  • To make a rushing, whistling, or sighing sound; emit a hollow murmur; murmur or sigh like the wind.
  • To breathe in or as in sleep.
  • To utter in a whining or monotonous tone.
According to the OED, from the 16th century, this word is 'almost exclusively Scots and northern dialect until adopted in general literary use in the 19th.'
Related